HER2 Targeted ADCs Clinical Data

CME

Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: May 05, 2025

Expiration: May 04, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In the DESTINY-PanTumor02 trial assessing treatment with trastuzumab deruxtecan in patients with HER2 expressing solid tumors, which gynecologic cancer subtype demonstrated the highest objective response rate, of approximately 85%?